Despite use of tecovirimat since the beginning of the 2022 mpox outbreak, few data have been published on its antiviral effect in humans

Despite use of tecovirimat since the beginning of the 2022 mpox outbreak, few data have been published on its antiviral effect in humans; this study predicts the impact of early tecovirimat administration on the time to viral clearance in patients with mpox infection, using an integrative modeling approach combining pre-clinical and clinical data

#####

In your coverage, please use this URL to provide access to the freely available paper in PLOS Biology:   http://journals.plos.org/plosbiology/article?id=10.1371/journal.pbio.3002249

Article Title: Early administration of tecovirimat shortens the time to mpox clearance in a model of human infection

Author Countries: France, Spain, United Kingdom, United States, Papua New Ginea

Funding: BTN received funding from IAME UMR 137, Université Paris Cité, INSERM, F-75018, Paris, France (https://www.iame-research.center/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

END